Personalised brain stimulation could improve life for Parkinson’s sufferers
Researchers in Oxford have made a landmark breakthrough towards improving the treatment of advanced Parkinson’s disease.
The Oxford University team based at the John Radcliffe Hospital has successfully trialled an advanced deep brain stimulation system that actively detects and responds to a patient’s brainwaves to reduce symptoms.
This personalised system, using a brain-computer interface, proved more effective than conventional stimulation and, by using less than half the power of existing systems, it could reduce the need for repeat operations to replace batteries.
Deep brain stimulation (DBS) is used to treat the difficulties in moving and involuntary shaking experienced by those living with advanced Parkinson’s disease, although it is not suitable for all patients. It involves permanently inserting electrodes into the brain to deliver electrical impulses. This stimulation cancels out the signal or “brain wave” causing the symptoms.
At present DBS therapy delivers continuous electrical stimulation to the brain. But the new “adaptive” system is a significant refinement and only delivers electrical stimulation when it detects the brainwaves responsible for causing the symptoms.
The proof of concept study, published online today by the journal Annals of Neurology, was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (a collaboration between Oxford University Hospitals NHS Trust and Oxford University), the Medical Research Council and The Wellcome Trust.
Peter Brown, Professor of Experimental Neurology at the University of Oxford and Consultant Neurologist at Oxford’s John Radcliffe Hospital, led the study.
He said: “Parkinson’s symptoms fluctuate on a moment by moment basis and the brain signal activity causing symptoms is not continuous, it comes in bursts. By only delivering stimulation when these bursts are detected you increase the effectiveness and reduce the amount of electrical stimulation delivered to the brain, reducing power consumption.
“DBS treatment is used by Parkinson sufferers for many years. We believe reducing the amount of electrical stimulation will lower the risk of side effects, although further research is needed on this aspect.” Potential side effects of deep brain stimulation can include speech and cognitive deterioration.
Prof Brown said a major advantage of adaptive DBS was the potential to significantly extend battery life.
He added: “At present patients need an operation every three or four years to replace the battery. These are elderly patients who are operated on under general anaesthetic. By extending battery life we can reduce the need for these operations.”
The adaptive system was trialled with eight patients. The trial was for 10 minute periods and compared to the effect of no stimulation, constant stimulation and randomised intermittent stimulation.
Prof Brown said: “We have believed for some time that this adaptive system could work, but this study has now proved the concept. Our conclusions were backed by independent assessment from experts at University College London.
“However, this was a small-scale proof of concept study. We now need to trial the system for longer periods. For anything longer than a few hours we will need to overcome technological hurdles in terms of miniaturising the system.
“The ultimate goal is a closed loop system small enough to be implanted in the body, similar to conventional DBS systems.”